The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers
Abstract
Objective: To assess the safety/tolerability and perform a preliminary efficacy evaluation of a multiple-dosing regimen of recombinant human vascular endothelial growth factor (VEGF 165 or rhVEGF; telbermin) applied topically to chronic diabetic neuropathic foot ulcers. Method: Subjects with type 1 or 2 diabetes mellitus were randomised to receive either topical applied telbermin (72µg/cm 2) (n=29) or placebo (n=26) treatment to the foot ulcer surface in conjunction with standard ulcer care. Subjects received treatment every 48 hours (maximum three doses per week) for up to six weeks. Weekly 35mm photography, quantitative planimetry and physical examinations documented the ulcer appearance, surface area and stage. Safety endpoints included incidence of clinically significant hypotension, adverse events and ulcer infection. Exploratory efficacy endpoints included percentage reduction in total ulcer surface area, incidence of complete ulcer healing and time to complete ulcer healing. Results: Incidence of adverse events was comparable in the two treatment groups. None of the adverse events were attributed to study drug, and no hypotension was observed as a result of telbermin treatment. Occurrence of infected study ulcers appeared to be balanced between the treatment groups. Positive trends suggestive of potential signals of biological activity were observed for incidence of complete ulcer healing (41.4% telbermin versus 26.9% placebo at day 43 [P=0.39]) and time to complete ulcer healing (25th percentile of 32.5 days telbermin versus 43.0 days placebo [log-rank P=0.13]). Conclusion: The topical application of telbermin 72µg/cm2 three times a week for up to six weeks appeared to be well tolerated. Further studies are required to characterise the safety/efficacy of telbermin more completely. Declaration of interest: Paul S. Kwon, Sarah M. Gray and Christopher J. Lynch are employed by Genentech, and own Genentech stock. Tim J. Breen was employed by Genentech before February 2006 and owns Genentech stock. Charles P. Semba was employed by Genentech before December 2007 and owns Genentech stock.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Cited by
Wound repair and regeneration: Mechanisms, signaling, and translation
Eming, S. A., Martin, P., & Tomic-Canic, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009337 · Cited by 3,562
Vascular Endothelial Growth Factor and Angiogenesis in the Regulation of Cutaneous Wound Repair
Johnson, K. E., & Wilgus, T. A. (2014) · Advances in Wound Care · doi:10.1089/wound.2013.0517 · Cited by 1,100
Martino, M. M., Tortelli, F., Mochizuki, M., Traub, S., Ben-David, D., Kuhn, G. A., Müller, R., Livne, E., Eming, S. A., & Hubbell, J. A. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002614 · Cited by 459
Skin tissue regeneration for burn injury
Shpichka, A., Butnaru, D., Bezrukov, E. A., Sukhanov, R. B., Atala, A., Burdukovskii, V., Zhang, Y., & Timashev, P. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1203-3 · Cited by 417
Zhao, S., Li, L., Wang, H., Zhang, Y., Cheng, X., Zhou, N., Rahaman, M. N., Liu, Z., Huang, W., & Zhang, C. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.02.112 · Cited by 394
Metadata
- Authors
- Hanft, J. R., Pollak, R. A., Barbul, A., Gils, C. V., Kwon, P. S., Gray, S. M., Lynch, C. J., Semba, C. P., & Breen, T. J.
- Venue
- Journal of Wound Care
- Publisher
- Mark Allen Group
- Published
- 2008-01
- Volume
- 17
- Issue
- 1
- Pages
- 30-37
- ISSN
- 0969-0700 (ISSN-L)
- 2052-2916
- OpenAlex
- W2077171235
- Cited by
- 159
- References
- 1
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. https://app.cochat.ai/papers/10.12968/jowc.2008.17.1.27917
- The paper
- Hanft, J. R., Pollak, R. A., Barbul, A., Gils, C. V., Kwon, P. S., Gray, S. M., Lynch, C. J., Semba, C. P., & Breen, T. J. (2008). Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. Journal of Wound Care. https://doi.org/10.12968/jowc.2008.17.1.27917
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.